BioWorld

Jan. 21, 2003

Amgen Hits Endpoints In First Enbrel Psoriasis Phase III Trial

The first of two Enbrel Phase III trials in psoriasis hit its primary and secondary endpoints, pushing Amgen Inc. to the halfway point in its quest to grow the blockbuster drug through the addition of another large market. (BioWorld Today) Read More

NPS's Phase III Bone Treatment Tested In Shuttle's Microgravity

FDA's Authority Over Cloning Questioned At Council Meeting

Holiday Notice

BioWorld's offices were closed Monday in observance of the Martin Luther King Jr. holiday in the U.S. No issue was published that day. Read More

Amylin Sells 9.2M Shares, Raises $152.7M For Symlin

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for March 31, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026